Barclays Maintains Overweight Rating for Replimune Group: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Barclays has maintained its Overweight rating on Replimune Group (NASDAQ:REPL) but reduced its price target from $50.00 to $13.00. Replimune's shares are currently trading at $6.77, and the new price target suggests a potential upside of 92.02%. Replimune is a clinical-stage biotech company focused on developing oncolytic immunotherapies for cancer treatment using its proprietary RPx platform.

December 06, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Replimune Group but lowers the price target from $50 to $13. The stock's current price is $6.77, and the new target implies a significant upside.
The maintenance of an Overweight rating by Barclays indicates a positive outlook on Replimune Group, which could instill investor confidence. However, the reduction in the price target might reflect a recalibration of expectations, possibly due to market conditions or company performance. Despite the lower target, the substantial potential upside from the current price could drive short-term interest and upward price movement.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100